A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).

Nathan A.  Pennell

Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cota Healthcare; G1 Therapeutics; Genentech; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Sanofi/Regeneron; Viosera Therapeutics; Xencor

Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Heat Biologics (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); WindMIL (Inst)

Lori J.  Wirth

Consulting or Advisory Role - Bayer; Blueprint Medicines; Coherus Biosciences; Eisai; Exelixis; Lilly; Loxo; Merck; Morphic Therapeutic

Research Funding - Ayala Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst)

Expert Testimony - Eisai

Other Relationship - PDS Biotechnology

Justin F.  Gainor

Employment - Ironwood Pharmaceuticals (I)

Stock and Other Ownership Interests  - Ironwood Pharmaceuticals (I)

Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda

Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; ITeos Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda

Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)

Julia K  Rotow

Honoraria - AstraZeneca; Chia Tai Tianqing; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Pfizer; Regeneron; Takeda

Consulting or Advisory Role - Abbvie; AstraZeneca; Gritstone Bio; Lilly; Regeneron; Takeda

Melissa Lynne  Johnson

Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)

Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi

Todd Michael  Bauer

Employment - Tennessee Oncology

Consulting or Advisory Role - AstraZeneca; Bayer; Loxo; Pfizer

Speakers' Bureau - Bayer; Bristol-Myers Squibb; Lilly

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); Top Alliance BioScience (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pfizer

Matthias  Kroiss

Honoraria - Lilly

Consulting or Advisory Role - Bayer; Eisai; Ipsen; Lilly; Loxo

Research Funding - Lilly

Travel, Accommodations, Expenses - Lilly

Vineeth  Sukrithan

Consulting or Advisory Role - GE Healthcare

Hyunseok  Kang

Honoraria - Axis Medical Education; Cancer Expert Now

Consulting or Advisory Role - Achilles Therapeutics; Bayer; Coherus Biosciences; Exelixis; GlaxoSmithKline; MitoImmune; PIN therapeutics; Prelude Therapeutics; Tempus

Research Funding - Ayala Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Kura Oncology (Inst); Lilly (Inst); NeoImmuneTech (Inst); PDS Biotechnology (Inst); Prelude Therapeutics (Inst)

Francis P.  Worden

Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck Sharp & Dohme; Regeneron

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Loxo; Merck; Regeneron

Research Funding - Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst)

Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme

Christine M.  Bestvina

Consulting or Advisory Role - Abbvie (I); AstraZeneca; Bristol-Myers Squibb/Celgene; Creative Educational Concepts; Curio Science; CVS; Genentech; Janssen; Jazz Pharmaceuticals; Novartis; OncLive Clinical Congress Consultants; Sanofi/Regeneron; Seagen; Takeda

Speakers' Bureau - Merck

Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb

Julien  Hadoux

No Relationships to Disclose

Philippe Alexandre  Cassier

Honoraria - Amgen; ITeos Therapeutics; Janssen

Consulting or Advisory Role - OSE Immunotherapeutics

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Roche

Antoine  Italiano

Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche

Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche

Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche

Patents, Royalties, Other Intellectual Property - BMS

Juergen  Wolf

Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma Europe; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo; Loxo/Lilly; MSD; Novartis; Pfizer; Roche; Seagen; Takeda

Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen; Takeda

Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer

Marcia S.  Brose

Honoraria - Bayer; Eisai; Lilly

Consulting or Advisory Role - Bayer; Blueprint Medicines; Eisai; Exelixis; Lilly; Loxo

Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Lilly (Inst); Loxo (Inst)

Emin  Avsar

Employment - Bristol Myers and Squibb; Lilly; Novartis Institutes for BioMedical Research

Stock and Other Ownership Interests  - Abbvie; Bristol MyersSquibb; GlaxoSmithKline; Lilly; Seelos Therapeutics

Michael D.  Axelson

Employment - Bristol-Myers Squibb; Loxo/Lilly; Tempus

Stock and Other Ownership Interests  - Bristol-Myers Squibb

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Loxo/Lilly; Tempus

Vivek  Subbiah

Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm

Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)

Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar

Other Relationship - Medscape

Alexander E.  Drilon

Stock and Other Ownership Interests  - Treeline Biosciences

Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV More; Sirio Libanes Hospital; TP Therapeutics; Verastem

Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences

Research Funding - Foundation Medicine

Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)

Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva